Search

Your search keyword '"P. Kwo"' showing total 36 results
Start Over Author "P. Kwo" Topic business.industry
36 results on '"P. Kwo"'

1. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection

Author

H. Bae, Rmf Yuen, WS Ayoub, J Lalezari, Eugene R. Schiff, R Colonno, M Sulkowski, Hie-Won Hann, Alnoor Ramji, N Ravendhran, M Bennett, SC Chan, Magdy Elkhashab, P. Kwo, T Hassanein, Qi Huang, E Gane, S Fung, X. Ma, JS Park, T. Nguyen, SH Han, Ronald Nahass, S Knox, D. Dieterich, IM Jacobson, H Zayed, Maurizio Bonacini, and K Alves

Subjects
Hepatology, Chronic hepatitis, Hbeag negative, Reverse-transcriptase inhibitor, business.industry, Medicine, In patient, business, Virology, Hepatitis b core, medicine.drug
Published
2020
Full Text
View/download PDF

2. PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL

Author

C. Pan, H.W. Hann, L. Frazier, P. Kwo, K. Cox, R. Reddy, H. Bae, Michael P. Curry, W.R. Kim, V. Ankoma-Sey, M. Tong, Douglas T. Dieterich, Scott Milligan, and Nezam H. Afdhal

Subjects
medicine.medical_specialty, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Hepatitis B, Clinical care, medicine.disease, business, Tenofovir alafenamide
Published
2020
Full Text
View/download PDF

3. Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy

Author

P. Kwo, Jan Sperl, R. Talwani, Christophe Hézode, Gregory J. Dore, Peggy Hwang, J. Long, Barbara Haber, and Michael N. Robertson

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatitis C virus genotype, medicine, Elbasvir, Grazoprevir, Hormone replacement therapy, business, Gastroenterology
Published
2018
Full Text
View/download PDF

4. PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US

Author

L. Frazier, H.W. Hann, H. Bae, V. Ankoma-Sey, W.R. Kim, Douglas T. Dieterich, J. Radtchenko, Nezam H. Afdhal, M. Tong, Scott Milligan, C. Pan, R. Reddy, P. Kwo, and Michael P. Curry

Subjects
Clinical Practice, Oncology, medicine.medical_specialty, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Hepatitis B, medicine.disease, business, Tenofovir alafenamide
Published
2019
Full Text
View/download PDF

5. Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis

Author

Christophe Hézode, M.B. Ferret, P. Kwo, Graham R. Foster, S. Zeuzem, Pol Stanislas, C.-W. Lin, I.C. Ng, Fred Poordad, Jens Kort, Tami Pilot-Matias, E.J. Gane, Neddie Zadeikis, Y. Lei, Stanley Wang, Tarik Asselah, Federico J. Mensa, Kosh Agarwal, Armen Asatryan, David L. Wyles, and Kris V. Kowdley

Subjects
Prior treatment, medicine.medical_specialty, Hepatology, business.industry, Phase (matter), Internal medicine, medicine, In patient, Hepatitis C, Glecaprevir / pibrentasvir, medicine.disease, business, Gastroenterology
Published
2018
Full Text
View/download PDF

6. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

Author

Stuart C. Gordon, Rvikumar Vemuru, Mark Eisner, Jay Cowan, James Ehrlich, Alain Ades, Clifford A. Brass, Micheal David Bernstein, Steve Chen, Donald Hillebrand, Donald Wadland, Lyle Shlager, C. Smith, Lou Gelrud, Mark Levstik, Helen Wong, Stephen A. Harrison, Andrew Nelson, Raj Bhandari, David Dies, Mordechai Rabinovitz, Edward A. Galen, B. Freilich, K. Digregorio, Curt Hagendom, Thomas Hargrave, Paul Bermanski, David Maccini, Samuel B. Ho, Ronald Pruitt, Terence Reisman, Thomas Allen, Robert S. Brown, Michael Cox, David Schulman, Ramsey Cheung, Fred Kilby, J. Lynn Cochran, Thomas McDonald, James Thornton, John Jolley, John Serini, Albert D. Min, Fredrich Loura, Lino Deguzman, Luis Marsano, Robert Finkel, Helen S. Te, Michael G Rahmin, Mark Jonas, Kip Lyche, Jean Luc Szpakowski, George Abraham, Alex D. Lee, Pabak Mukhopadhyay, Firdous Siddiqui, Robert Strauss, William Kaplan, Michael Ryan, Eliot Godofsky, Stephen J. Lanspa, Lawton Shick, Jose Franco, Louis Griffel, Rise Stribling, Avanish Aggarwal, Clive Albert, Thomas Rosenfield, Rockford Yapp, Vijay Balan, Arthur Berman, Nezam H. Afdhal, Maurice Cerulli, Paul Yudelman, Robert Herring, Donate Ricci, Michael Henry, Michael Bloom, Daniel Meline, Barry Migicovsky, Peter Varunok, Peter W Gardner, Gerald Siciliano, Natarjan Bala, Craig J. Peine, P. Kwo, Thomas Noble, David F. Stein, Thuan T. Nguyen, Geoffrey Zucker, Julie E Spivack, John Kichner, Robert G. Gish, Michael Fried, Murali Shankar, Norman Gitlin, James E. Nelson, David Hurwich, Darrell Schwertner, Ronald Wasserman, Douglas D. Dalke, Thai Van Pham, Geronimo Sahagun, Norah A. Terrault, Naoky Tsai, Steven Han, Tarek Hassanein, Thomas Sepe, Seth Richter, Howard Paul Monsour, Micheal Lyons, R. Agrawal, Bennett Cecil, Joseph Polito, Douglas Levin, James Srour, Allan Weston, Larry Weprin, Raymond Kenny, Edward Lebovics, Michael Demicco, Terry Box, Kenneth Diamond, Lawrence Kim, Stephen Kelly, Martin Black, Jeffrey Fenyves, Ellen Shaw, Raymond A. Rubin, James E. Cox, Franco Felizarta, John E. Gross, Ira Lobis, David H. Van Thiel, Bonnie Bock, Lawrence Stein, James D. Lewis, Steven Palley, Ronald Rinker, Joanna Ready, Vinod K. Rustgi, Michael Epstein, David H Berman, Gary Matusow, Walid Baddoura, Gerond Lake-Bakaar, John S. Goff, Scott Wiesen, Neil Brodsky, Fredric Regenstein, Arnold Levin, Bhupinder S. Anand, Stephen Esposito, K. Rajender Reddy, Lisa Ozick, Adil E. Wakil, Karl Esrason, Pierre Nader, David Nunes, David Feldman, K. Ganeshappa, Alan Fixelle, Martha Ghosh, Douglas Brouillette, Victor Araya, Hillel Tobias, David Pound, Louis R. Lambiase, S. Lawrence Rothman, Mark J. Murphy, Jonathan David, James Levin, Steve Carlson, Nathan Kam, Michael S. Dragutsky, Trong Nguyen Tuan, Graham Woolf, Whit Knapple, Donna Goldman, Kenneth R. DeVault, Simon Cofrancesco, Mitchell L. Shiffman, Charles Bedard, Paul Y. Kwo, Rodger Perez, Steven L. Flamm, Keith Tolman, Hulya Levendoglu, Timothy Cavacini, Robert Reindollar, Vance VanDrake, Donald M. Jensen, David Winston, Robert A. Levine, Robert Manning, John R. Lake, John J. Santoro, Scott Becker, Mary Pat Pauly, John M. Vierling, Joseph DePasquale, Jorge Herrera, Diana Sylvestre, Natarajan Ravendhran, Mark Smith, Kevin Dye, M. Davis, Frank Klion, Kevin Behrle, Alan Epstein, William Lyles, Brian K. Hudes, Greg Galler, David I. Bernstein, Jonathon Jensen, Jeffery Cooley, Thomas J. Layden, Carl D'Angelo, Fredric D. Gordon, Myron Brand, David Gabbazaideh, Leon Rigberg, Neville R. Pimstone, Jonathan McCone, Ira M. Jacobson, Tim M Jenkins, John W. King, Harry Matossian, William A. Ross, and Rudra Rai

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Genotype, Hepatitis C virus, Alpha interferon, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Antiviral Agents, Gastroenterology, Polyethylene Glycols, chemistry.chemical_compound, Pegylated interferon, Internal medicine, Ribavirin, medicine, Humans, Prospective Studies, Interferon alfa, Aged, Dose-Response Relationship, Drug, Hepatology, business.industry, Body Weight, Interferon-alpha, Middle Aged, Hepatitis C, Recombinant Proteins, Surgery, Treatment Outcome, chemistry, RNA, Viral, Peginterferon alfa-2b, Drug Therapy, Combination, Female, business, Viral load, medicine.drug
Abstract

This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were randomly assigned to receive PEG-IFN alfa-2b 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based (800-1400 mg/day) RBV for 48 weeks (patients with genotype 1, 4, 5, or 6) and for 24 or 48 weeks (genotype 2/3 patients). Primary end point was sustained virologic response (undetectable [

Published
2007
Full Text
View/download PDF

7. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Author

P. Pockros, Ira M. Jacobson, A. M. Di Bisceglie, Gregory T. Everson, Mark E. Mailliard, J.R. Spivey, H.E. Vargas, Thomas G. Stewart, C.A. Kerr, K.R. Reddy, H.A. Elbeshbeshy, Gyongyi Szabo, M.S. Sulkowski, Norah A. Terrault, Nezam H. Afdhal, P. Kwo, K. Rajender Reddy, T.N. Hawkins, Coleman Smith, Eugene R. Schiff, J. Lim, I.M. Jacobson, G. Morelli, Michael W. Fried, Lynn M. Frazier, Andrew J. Muir, Mohamed Hassan, Jordan J. Feld, Giuseppe Morelli, Federico Hinestrosa, Hugo E. Vargas, Mitchell L. Shiffman, Richard K. Sterling, Adrian M. Di Bisceglie, Imtiaz Alam, Nancy Reau, Ziv Ben-Ari, Mark S. Sulkowski, A. Williams, R.T. Chung, J. Darling, C. Trautwein, Josh Levitsky, Stefan Zeuzem, Jonathan M. Fenkel, J. Bredfeldt, Rolland C. Dickson, Kenneth E. Sherman, Ananthakrishnan Ramani, R.S. Brown, Jama M. Darling, M.W. Fried, A. Kuo, David R. Nelson, Joseph S. Galati, Jacqueline G. O'Leary, W. Harlan, D. Nelson, Joseph K. Lim, A.S. Lok, Michael P. Manns, Alexander Kuo, Robert S. Brown, Brian L. Pearlman, K. Watts, and S.C. Gordon

Subjects
Simeprevir, Male, Time Factors, Sofosbuvir, Hepacivirus, medicine.disease_cause, Telaprevir, chemistry.chemical_compound, 0302 clinical medicine, 030212 general & internal medicine, Prospective Studies, Aged, 80 and over, Gastroenterology, virus diseases, Middle Aged, Viral Load, Hepatitis C, Treatment Outcome, RNA, Viral, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, Genotype, Hepatitis C virus, Antiviral Agents, Article, 03 medical and health sciences, Young Adult, Boceprevir, Internal medicine, Ribavirin, medicine, Humans, Aged, Hepatology, business.industry, digestive system diseases, Discontinuation, Regimen, chemistry, Immunology, North America, business, Biomarkers
Abstract

Background & Aims The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America. Methods We collected demographic, clinical, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TARGET—a prospective observational cohort study of patients undergoing HCV treatment in routine clinical care settings. From January through October 2014, there were 836 patients with HCV genotype 1 infection who began 12 weeks of treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had cirrhosis. Most patients had failed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), defined as the level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatment—a 2-week window). Logistic regression models with inverse probability weights were constructed to adjust for baseline covariates and potential selection bias. Results The overall SVR rate was 84% (675 of 802 patients, 95% confidence interval, 81%–87%). Model-adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% of participants, respectively. Conclusions In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811.

Published
2015

8. Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study

Author

M. Li, John M. Vierling, A. Sobhonslidsuk, B. Evans, S. Khemichian, A. Dev, S.C. Gordon, William Rosenberg, R. Talwani, Velimir A. Luketic, Stanislas Pol, George V. Papatheodoridis, N. Assy, P. Kwo, L. Morgan, D. Guyader, and J.M. Arduino

Subjects
Health related quality of life, medicine.medical_specialty, Blood Disorder, Hepatology, Chronic hepatitis, business.industry, Internal medicine, medicine, Elbasvir, Grazoprevir, In patient, business, Gastroenterology, Virus
Published
2017
Full Text
View/download PDF

9. Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis

Author

Mordechai Rabinovitz, Mindie H. Nguyen, E.J. Lawitz, O. Khalid, Aasim Sheikh, Mitchell L. Shiffman, Daniel Bernstein, Catherine A.M. Stedman, Di An, Myron J. Tong, P. Kwo, J. Poulos, Naoky Tsai, S.C. Gordon, E.J. Gane, Michael P. Curry, L.M. Stamm, Ira M. Jacobson, Hadas Dvory-Sobol, D.M. Brainard, Kris V. Kowdley, Kimberly L. Beavers, Nancy Reau, Brian L. Pearlman, G.T. Everson, J.C. Yang, and John G. McHutchison

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.disease, Gastroenterology, Sofosbuvir/velpatasvir, Therapy naive, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Genotype, Medicine, 030211 gastroenterology & hepatology, business, Short duration
Published
2016
Full Text
View/download PDF

10. Comparison of NaI(Tl), CdTe, and HgI2 surgical probes: Effect of scatter compensation on probe performance

Author

H.B. Barber, James M. Woolfenden, Harrison H. Barrett, D. P. Kwo, and T. S. Hickernell

Subjects
Physics, Optics, business.industry, Scattering, Instrumentation, Detector, Compton scattering, Window (computing), General Medicine, business, Particle detector, Energy (signal processing), Background radiation
Abstract

Spatial variation in the background source distribution makes tumor detection difficult for single‐detector probes. Using a single energy window that brackets the photopeak helps discriminate against background events dominated by Compton scattering. Another approach is to use the information provided by an additional window in the Compton region. The performances of NaI(Tl), CdTe, and HgI2 surgical probes have been compared under realistic simulations of a tumor‐staging procedure using optimal single‐sided energy windows and a two‐window scatter‐subtraction technique. Results showed that despite the differences in energy resolution of the detectors, the performances of the probes in a variable background were similar when optimal single energy windows were used. When the background variations were large, using information provided by a second window improved probe performance.

Published
1991
Full Text
View/download PDF

11. Comparison of NaI(Tl), CdTe, and HgI2 surgical probes: Physical characterization

Author

H.B. Barber, James M. Woolfenden, Harrison H. Barrett, T. S. Hickernell, G. Entine, D. P. Kwo, and C. Ortale Baccash

Subjects
Materials science, Physics::Instrumentation and Detectors, business.industry, Counting efficiency, General Medicine, Scintillator, Photoelectric effect, Cadmium telluride photovoltaics, Particle detector, Semiconductor detector, Condensed Matter::Materials Science, Optics, Semiconductor, Scintillation counter, business
Abstract

The physical properties of three surgical probes containing different radiation detectors are compared: a NaI(Tl) scintillator with a flexible, fiber-optic light guide, and two semiconductor detectors that operate at room temperature, CdTe and HgI2. Also compared are spectra, energy resolutions, and counting efficiencies measured at a variety of gamma-ray energies between 30 and 1000 keV. The energy resolution of the NaI probe is substantially poorer than that of either semiconductor probe due in part to light losses in coupling the scintillator to the fiber optics. The semiconductor probes have complex spectral response due to charge-carrier trapping and K x-ray escape, and not all photoelectric interactions in these detectors contribute to the useful part of the photopeak. Above 120 keV the counting efficiency for the NaI probe is an order of magnitude higher than for the CdTe and HgI2 probes. Both energy resolution and counting efficiency are slightly better for the HgI2 probe than for the CdTe probe.

Published
1991
Full Text
View/download PDF

12. High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin among Patients with Decompensated Cirrhosis who Underwent Liver Transplant during Participation in the Solar-1 and -2 Studies

Author

Beat Müllhaupt, Markus Peck-Radosavljevic, Yves Horsmans, P. Kwo, P. Kumar, Les Lilly, Norah A. Terrault, Shampa De-Oertel, Christophe Duvoux, Robert S. Brown, Sarah Arterburn, F. Durand, Hugo E. Vargas, Bernard Willems, Eric M. Yoshida, M. Rizzetto, Kosh Agarwal, John G. McHutchison, D.M. Brainard, and Hadas Dvory-Sobol

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, 030230 surgery, Decompensated cirrhosis, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, medicine, LEDIPASVIR/SOFOSBUVIR, business, 030217 neurology & neurosurgery
Published
2016
Full Text
View/download PDF

13. High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

Author

P. Kwo, Stanley Wang, Jens Kort, Teresa I. Ng, E.J. Gane, Simone I. Strasser, Federico J. Mensa, Sandra S. Lovell, Andrew J. Muir, David L. Wyles, Stephen D. Shafran, C.-W. Lin, and Maurizio Bonacini

Subjects
03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, 030220 oncology & carcinogenesis, Internal medicine, Genotype, medicine, 030211 gastroenterology & hepatology, business, Gastroenterology
Published
2016
Full Text
View/download PDF

14. Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentretreatment Protocol

Author

B. Anduze-Faris, Rajender Reddy, A.A. Napoli, P. Kwo, C.S. Pico, Saro Khemichian, Robert H. Brown, Jama M. Darling, and Michael Fried

Subjects
medicine.medical_specialty, Cirrhosis, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Hcv recurrence, Decompensated cirrhosis, medicine.disease, 030226 pharmacology & pharmacy, Gastroenterology, Advanced fibrosis, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, medicine.drug
Published
2016
Full Text
View/download PDF

15. 100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis

Author

Federico J. Mensa, Benedict Maliakkal, Jens Kort, Mitchell L. Shiffman, P. Kwo, Stanley Wang, David L. Wyles, E.J. Gane, Teresa I. Ng, Fred Poordad, Ran Liu, and C.-W. Lin

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Ribavirin, medicine.disease, Gastroenterology, Therapy naive, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, Genotype, Medicine, 030211 gastroenterology & hepatology, 030212 general & internal medicine, business
Published
2016
Full Text
View/download PDF

16. 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS

Author

Lisa D. Pedicone, M.P. Manns, S.L. Flamm, P. Kwo, Frans A. Helmond, Fred Poordad, Frank J. Dutko, Savino Bruno, Jean-Pierre Bronowicki, W. Deng, R. Esteban, Bruce R. Bacon, S. Zeuzem, John M. Vierling, Janice Wahl, Kenneth Koury, and Mark J. DiNubile

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Combination therapy, business.industry, PEGINTERFERON/RIBAVIRIN, medicine.disease, Gastroenterology, Clinical trial, chemistry.chemical_compound, chemistry, Meta-analysis, Boceprevir, Internal medicine, medicine, business
Published
2013
Full Text
View/download PDF

17. P1234 SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION

Author

A. Zhou, N. Mobashery, Michael N. Robertson, Lawrence Serfaty, Christopher L. Gilbert, Savino Bruno, Ira M. Jacobson, P. Kwo, Christophe Hézode, Janice Wahl, and Peggy Hwang

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Hepatitis C virus, medicine.disease_cause, Gastroenterology, Therapy naive, chemistry.chemical_compound, chemistry, Internal medicine, Genotype, medicine, Peginterferon alfa-2b, business, medicine.drug
Published
2014
Full Text
View/download PDF

19. P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY

Author

P. Kwo, Richard Gilroy, J. Denning, Lewis W. Teperman, Lindsay McNair, Xavier Forns, M.P. Manns, William T. Symonds, Richard J. C. Brown, Andrew J. Muir, Michael P. Curry, Robert J. Fontana, E.J. Gane, Norah A. Terrault, Sarah Arterburn, Michael Charlton, John G. McHutchison, and Didier Samuel

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, Ribavirin, Liver transplantation, Gastroenterology, chemistry.chemical_compound, Multicenter study, chemistry, Internal medicine, Medicine, Recurrent hepatitis, business, medicine.drug
Published
2014
Full Text
View/download PDF

20. O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

Author

Paul J. Pockros, P. Kwo, Phillip S. Pang, M.S. Sulkowski, Sanjeev Arora, Hadas Dvory-Sobol, A. M. Di Bisceglie, John G. McHutchison, William T. Symonds, Yanni Zhu, Jenny C. Yang, Rajender Reddy, and Nezam H. Afdhal

Subjects
Ledipasvir, medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, Fixed-dose combination, Gastroenterology, Treatment experienced, chemistry.chemical_compound, chemistry, Internal medicine, Genotype, medicine, business, medicine.drug
Published
2014
Full Text
View/download PDF

21. O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION

Author

Xavier Forns, Helen S. Te, F.D. Gordon, Parvez S. Mantry, Regis A. Vilchez, Hugo E. Vargas, James R. Burton, Carolyn M. Setze, Eoin Coakley, Wangang Xie, Norah A. Terrault, J. Levitsky, Robert S. Brown, P. Kwo, and Prajakta S. Badri

Subjects
medicine.medical_specialty, Hepatology, business.industry, Interferon free, Ribavirin, Phases of clinical research, Gastroenterology, Regimen, chemistry.chemical_compound, Hcv genotype 1, chemistry, Internal medicine, Medicine, business
Published
2014
Full Text
View/download PDF

22. 23 PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR HEPATITIS C RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANTATION (OLT): FINAL RESULTS FROM THE PROTECT STUDY

Author

Jeffrey S. Crippin, P. Kwo, R.J. Ghalib, F.D. Gordon, X. Yu, Thomas D. Schiano, Robert S. Brown, Kimberly A. Brown, Hugo E. Vargas, E. Chaudhri, and Lisa D. Pedicone

Subjects
medicine.medical_specialty, Hepatology, Orthotopic liver transplantation, business.industry, Ribavirin, Hepatitis C, medicine.disease, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, Peginterferon alfa-2b, business, medicine.drug
Published
2010
Full Text
View/download PDF

23. [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA

Author

N.N. Zein, D. Bright, John G. McHutchison, M.L. Shiftman, P. Kwo, S.C. Gordon, B. Freilich, Ira M. Jacobson, J. Lekstrom-Himes, M. Al-Adhami, F.E. Massari, Reem Ghalib, Eugene R. Schiff, A. Reuben, M. Swaim, S.L. Flamm, T.R. Riley, and E.J. Lawitz

Subjects
chemistry.chemical_compound, Hepatology, CpG site, chemistry, Hcv genotype 1, Pegylated interferon, business.industry, Ribavirin, medicine, business, Virology, medicine.drug
Published
2007
Full Text
View/download PDF

24. Curved-grating surface-emitting DFB lasers and arrays

Author

James E. Logue, Jeffrey J. Powers, Deborah P. Kwo, Patricia A. Lee, Jeffrey S. Mott, Steven H. Macomber, Robert M. Dixon, Richard S. Setzko, and Bradley D. Schwartz

Subjects
Materials science, business.industry, Physics::Optics, Grating, Laser, Semiconductor laser theory, law.invention, Optics, Filamentation, law, Optoelectronics, Laser beam quality, business, Diffraction grating, Quantum well, Tunable laser
Abstract

A new method of producing nearly diffraction limited beam quality from high-power semiconductor lasers is presented. It is shown, both theoretically and experimentally, that well-designed grating curvature in surface-emitting distributed feedback lasers can alleviate the problems of multi-mode operation and filamentation in wide stripe devices. Surface-emitting devices of this type are capable of very high power without the optical damage limitations of edge-emitting lasers. A method for combining arrays of these lasers with series electrical wiring and precision optical alignment has been developed. A 64 element array was demonstrated that produced approximately 160 W of cm power and could be focused into a small spot.

Published
1997
Full Text
View/download PDF

25. 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

Author

David R. Nelson, P. Kwo, Fred Poordad, B. Bernstein, M.S. Sulkowski, G.T. Everson, Stefan Zeuzem, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Eric Lawitz, Graham R. Foster, Wangang Xie, Amit Khatri, and Lois Larsen

Subjects
Oncology, medicine.medical_specialty, chemistry.chemical_compound, Hepatology, chemistry, business.industry, Internal medicine, Ribavirin, Interferon free, medicine, In patient, business
Published
2013
Full Text
View/download PDF

26. 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR

Author

P. Kwo, Monika Vainorius, K.R. Reddy, M.S. Sulkowski, Brian L. Pearlman, Nezam H. Afdhal, Joy Peter, David R. Nelson, A. M. Di Bisceglie, Norah A. Terrault, Kenneth E. Sherman, Michael Fried, G.T. Everson, S.C. Gordon, Paul J. Pockros, Andrew J. Muir, Donald M. Jensen, Ira M. Jacobson, and Thomas G. Stewart

Subjects
medicine.medical_specialty, chemistry.chemical_compound, Hepatology, chemistry, Chronic hepatitis, business.industry, Internal medicine, Boceprevir, Medicine, Observational study, business, Telaprevir, medicine.drug
Published
2013
Full Text
View/download PDF

27. 13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION

Author

Reem Ghalib, G.T. Everson, P. Kwo, John G. McHutchison, Vinod K. Rustgi, B. Kanwar, A. M. Di Bisceglie, Mani Subramanian, John M. Vierling, J.D. Trenkle, and F. Hsieh

Subjects
NS3, Hepatology, business.industry, Ribavirin, Hepatitis C, medicine.disease, Virology, Treatment experienced, chemistry.chemical_compound, chemistry, Pegylated interferon, Genotype, Medicine, Protease inhibitor (pharmacology), business, NS5A, medicine.drug
Published
2013
Full Text
View/download PDF

28. 127 PHOSPHODIESTERASE POLYMORPHISMS MAY BE ASSOCIATED WITH BASELINE THYROID STIMULATING HORMONE (TSH) AND PEGINTERFERON TREATMENT INDUCED HYPOTHYROIDISM IN PATIENTS WITH CHRONIC HEPATITIS C

Author

Stephanie Noviello, P. Kwo, Jonathan McCone, Abanish Singh, Reem Ghalib, Alexander J. Thompson, Mingfu Zhu, R. Esteban, E.J. Lawitz, Thomas J. Urban, N. Bopari, Nezam H. Afdhal, L. Nyberg, David Goldstein, Kevin V. Shianna, Paul J. Clark, Kenneth Koury, Janice K. Albrecht, Hans L. Tillmann, M.S. Sulkowski, Andrew J. Muir, Mitchell L. Shiffman, Greg Galler, Lee Way-Shing, Ira M. Jacobson, John W. King, B. Freilich, Fred Poordad, Dongliang Ge, Clifford A. Brass, Kushang V. Patel, Lisa D. Pedicone, John G. McHutchison, and Robert Reindollar

Subjects
medicine.medical_specialty, Endocrinology, Hepatology, Thyroid-stimulating hormone, Chronic hepatitis, business.industry, Internal medicine, Medicine, Phosphodiesterase, In patient, business
Published
2011
Full Text
View/download PDF

29. 596 SUSTAINED VIROLOGICAL RESPONSE RATES IN PATIENTS ACHIEVING SLOW RESPONSE OR COMPLETE EARLY VIROLOGICAL RESPONSE (CEVR) WITH CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE DIRECT TRIAL

Author

P. Kwo, Giuseppe Morelli, Reem Ghalib, Norman Gitlin, K. Rothstein, Mitchell L. Shiffman, F. Mendes, Tarek Hassanein, Bruce R. Bacon, and Shobha Joshi

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Consensus interferon, Virological response, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, Slow response, business
Published
2009
Full Text
View/download PDF

30. 4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

Author

S.C. Gordon, P. Kwo, Ira M. Jacobson, Jonathan McCone, Natarajan Ravendhran, M. Davis, David Pound, E. Chaudhri, John M. Vierling, Kenneth Koury, Janice K. Albrecht, Frank H. Anderson, Clifford A. Brass, Eugene R. Schiff, Joseph S. Galati, R. Rubin, Lorenzo Rossaro, and E.J. Lawitz

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Phases of clinical research, Gastroenterology, Therapy naive, chemistry.chemical_compound, Chronic hepatitis, Sprint, chemistry, Boceprevir, Internal medicine, Genotype, medicine, Peginterferon alfa-2b, business, medicine.drug
Published
2009
Full Text
View/download PDF

31. Hartmann-Shack wavefront sensor using a binary optic lenslet array

Author

Mitch Haller, Deborah P. Kwo, George Damas, and William P. Zmek

Subjects
Physics, Wavefront, Optics, Sampling (signal processing), business.industry, Calibration, Astronomical interferometer, Wavefront sensor, business, Adaptive optics, Deformable mirror, High dynamic range
Abstract

We have used the advantages of the photolithographic process to build a Hartmann-Shack type wavefront sensor using a 65 X 50 element binary optic lens array as the wavefront sampling element. The inherent accuracy and versatility of the lithographic process has reduced sampling and calibration errors associated with classic Hartmann sensing by allowing the lens array geometry to be tailored to CCD detector geometry with extreme precision. Combined with a quad-cell centroiding algorithm and wavefront reconstruction routines based on the successive over relaxation (SOR) algorithm, we present a wavefront sensor with submicron spot position accuracy, uniform response curves for all spots in the array, high dynamic range, and relative insensitivity to laboratory environmental vibrations. Experimental results obtained during a comparison of its performance to established wavefront methods are presented.

Published
1991
Full Text
View/download PDF

32. 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC

Author

Jonathan McCone, Lisa D. Pedicone, P. Mukhopadhyay, P. Kwo, David Pound, E. Chaudhri, Eugene R. Schiff, John M. Vierling, Natarajan Ravendhran, Frank H. Anderson, S.C. Gordon, Janice K. Albrecht, Ira M. Jacobson, Joseph S. Galati, E.J. Lawitz, R. Rubin, M. Davis, and Lorenzo Rossaro

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Phases of clinical research, Gastroenterology, Therapy naive, chemistry.chemical_compound, chemistry, Sprint, Internal medicine, Boceprevir, Interim, Genotype, medicine, Peginterferon alfa-2b, business, medicine.drug
Published
2008
Full Text
View/download PDF

33. 730 Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response

Author

P. Kwo, B. Freilich, E. Masciari, Andrew J. Muir, R. Chalib, John G. McHutchison, Bruce R. Bacon, E. Tawitz, M. Al-Adhami, J.L. Himes, and M.L. Morris

Subjects
chemistry.chemical_compound, Hepatology, CpG site, chemistry, Hcv genotype 1, Pegylated interferon, business.industry, Ribavirin, medicine, business, Virology, medicine.drug
Published
2006
Full Text
View/download PDF

34. 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial

Author

P. Kwo, Ira M. Jacobson, S.L. Flamm, M.P. Pauley, Clifford A. Brass, Nezam H. Afdhal, Fredric Regenstein, Louis Griffel, Robert S. Brown, and B. Freilich

Subjects
Hepatology, business.industry, Genotype, Treatment outcome, medicine, Antiviral therapy, Hepatitis C, medicine.disease, business, Virology, Viral load
Published
2006
Full Text
View/download PDF

35. O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus

Author

F. Masciari, P. Kwo, John G. McHutchison, H.L. Davis, Andrew J. Muir, Mitchell L. Shiffman, Susan M. Efler, M. Al-Adhami, R. Ghalib, M.L. Morris, I.M. Jacobson, S.C. Gordon, J.L. Himes, N.H. Afdhal, E. Lawitz, B.R. Bacon, B. Freilich, and A. Vicari

Subjects
Agonist, Infectious Diseases, CpG site, business.industry, medicine.drug_class, Virology, Hepatitis C virus, Immunology, medicine, medicine.disease_cause, business
Published
2006
Full Text
View/download PDF

36. Probes Containing Gamma Radiation Detectors For In Vivo Tumor Detection And Imaging

Author

N.E. Hartsough, T. S. Hickernell, Harrison H. Barrett, H.B. Barber, James M. Woolfenden, and D. P. Kwo

Subjects
Physics, Background subtraction, Tumor detection, In vivo, business.industry, Radiation, Nuclear medicine, business, Small tumors, Particle detector, Biomedical engineering
Abstract

External gamma-camera imaging using tumor-seeking radiotracers has been shown to be insensitive in the task of identifying small tumors situated deep inside the body. Our approach is to use probes containing miniature radiation detectors which, when maneuvered close to a tumor, overcome the limitations of external imaging. We discuss our results from using such probes for bronchoscopic and surgical tumor detection. A limitation that prevents the detection of small tumors with these probes is the spatial variation of the background count rate due to distant background sources of high radiotracer uptake. We present two techniques for solving this problem geometric background subtraction and imaging.

Published
1989
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results